Surgical Outcomes After Neoadjuvant Pembrolizumab Plus Chemotherapy for Triple-Negative Breast Cancer: Results from the Randomized, Placebo-Controlled Phase 3 KEYNOTE-522 Study

Annals of Surgical Oncology 2026

View at publisher
Authors: Sherko Kuemmel, Peter A. Fasching, Peter Schmid, Nadia Harbeck, Masato Takahashi, Michael Untch, Jean-Francois Boileau, Javier Cortes, Rebecca Dent, Joyce O’Shaughnessy, Lajos Pusztai, Theodoros Foukakis
+8 more Yeon Hee Park, Rina Hui, Fatima Cardoso, Carsten Denkert, Liyi Jia, Wilbur Pan, Vassiliki Karantza, Heather McArthur
DOI: 10.1245/s10434-026-19121-2
Cited by: 2
References: 17

Fields of Study & Subjects

Breast Cancer Treatment Studies Cancer Immunotherapy and Biomarkers HER2/EGFR in Cancer Research

Publication details

Journal / source
Annals of Surgical Oncology
Publisher
Springer Science and Business Media LLC
Volume
33
Issue
6
Pages
5550–5557
Publication date
25 February 2026
Language
EN